LD 1600 LR 2402(03)
An Act To Require Health Insurers To Provide Coverage for Human Leukocyte Antigen Testing To Establish Bone Marrow Donor Transplantation Suitability
Fiscal Note for Bill as Amended by Committee Amendment " "
Committee: Insurance and Financial Services
Fiscal Note Required: Yes
Fiscal Note
Potential future biennium cost increase - General Fund
Fiscal Detail and Notes
Any additional costs to the State Employee Health Insurance Program are expected to be minor and can be absorbed within existing budgeted resources.  The Patient Protection and Affordable Care Act (ACA) requires States to defray the cost of mandated benefits not included in the ACA's Essential Health Benefits.  The Bureau of Insurance's report on LD 1600 to the Joint Standing Committee on Insurance and Financial Services estimated the cost of increased coverage due to LD 1600 to be approximately $48,000 per year.  The specifics of this required State payment under the ACA to defray the costs of this mandate (i.e., how much, what program(s) and when) cannot be determined at this time.